Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans

Hypertension

Volumn 30, Issue 4, 1997, Pages 918-921

  Cardillo, Carmine ^a   Kilcoyne, Crescence M ^a   Quyyumi, Arshed A ^a   Cannon III, Richard O ^a   Panza, Julio A ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Endothelium; Isoproterenol; Nitric oxide; Vasodilation; adrenergic receptors

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; BETA ADRENERGIC STIMULATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0030827912     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.4.918     Document Type: Article

References (35)

1. Kukovetz WR, Poch C, Holtzmann S. Cyclic nucleotides and relaxation of vascular smooth muscle. In: Vanhoutte PM, Leusen I, eds. Vasodilation. New York, NY: Raven Press; 1981:339-353.
2. Rubanyi G, Vanhoutte PM. Endothelium removal decreases relaxations of canine coronary arteries caused by β-adrenergic agonists and adenosine. J Cardiovasc Pharmacol. 1985;7:139-144.
3. Grace GC, MacDonald PS, Dusting GJ. Cyclic nucleotide interactions involved in endothelium-dependent dilatation in rat aortic rings. Eur J Pharmacol. 1988;148:17-24.
4. Kamata K, Miyata N, Kasuya Y. Involvement of endothelial cells in relaxation and contraction responses of the aorta to isoproterenol in naive and streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 1989;249:890-894.
5. Weir CJ, Gibson IF, Martin W. Effects of metabolic inhibitors on endothelium-dependent and endothelium-independent vasodilation of rat and rabbit aorta. Br J Pharmacol. 1991;102:162-166.
6. G-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5′-N-ethyl-carboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol. 1991;103:1725-1732.
7. Gray DW, Marshall I. Novel signal transduction pathway mediating endothelium-dependent β-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol. 1992;107:684-690.
8. Jackson WF, Busse R. Elevated guanosine 3′:5′-cyclic monophosphate mediates the depression of nitrovasodilator reactivity in endothelium-intact blood vessels. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:345-350.
9. Béa ML, Ghaleh B, Giudicelli JF, Berdeaux A. Lack of importance of NO in β-adrenoceptor-mediated relaxation of large epicardial coronary arteries in conscious dogs. Circulation. 1994;89:2799-2808.
10. α-nitro-L-arginine selectively inhibits vasodilator responses to acetylcholine and bradykinin in cats. Am J Physiol. 1991;260:H1025-H1029.
11. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
12. Bohme E, Graf H, Schultz G. Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic-GMP formation in smooth muscle and platelets. Adv Cycl Nucl Res. 1978;9:131-143.
13. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2: 997-1000.
14. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. Circulation. 1993;87:1468-1474.
15. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol. 1994;23:1610-1616.
16. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal-transduction pathway. Circulation. 1995; 91:1732-1738.
17. Stephenson JA, Summers RJ. Autoradiographic analysis of receptors on vascular endothelium. Eur J Pharmacol. 1987;134: 35-43.
18. Krebs EG. Role of the cyclic AMP-dependent protein kinase in signal transduction. JAMA. 1989;262:1815-1818.
19. Yatani A, Brown AM. Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science. 1989;245:71-74.
20. Bredt DS, Ferris CD, Snyder SH. Nitric oxide synthase regulatory sites. J Biol Chem. 1992;267:10976-10981.
21. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/ nitric oxide activity. Circulation. 1992;85:1927-1938.
22. Ghaleh B, Béa M-L, Dubois-Randé J-L, Giudicelli J-F, Hittinger L, Berdeaux A. Endothelial modulation of β-adrenergic dilation of large coronary arteries in conscious dogs. Circulation. 1995;92: 2627-2635.
23. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993;73:808-812.
24. Parent R, Al-Obaidi M, Lavallée M. Nitric oxide formation contributes to β-adrenergic dilation of resistance coronary vessels in conscious dogs. Circ Res. 1993;73:241-251.
25. Lincoln TM, Cornwall TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7:328-338.
26. Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilation. Eur Heart J. 1993;14(suppl I):141-148.
27. Eckly AE, Lugnier C. Role of phosphodiesterase III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J Pharmacol. 1994;113:445-450.
28. Vroom MB, Pfaffendorf M, van Wezel HB, van Zwieten PA. Effect of phosphodiesterase inhibitors on human arteries in vitro. Br J Anaesth. 1996;76:122-129.
29. Ono S, Ueda S, Sakuma T, Tanita T, Koike K, Fujimura S. Relaxation of human isolated pulmonary arteries by amrinone. J Cardiovasc Surg. 1996;37:177-181.
30. Daves M, Chowienczyk PJ, Ritter JM. Inhibition of nitric oxide (NO) synthesis in human forearm selectively inhibits β-adrenergic vasodilation. Circulation. 1996;94(suppl I):I-522. Abstract.
31. 2 and prostacyclin. Pharmacol Rev. 1979;30:293-331.
32. Radomski MW, Moncada S. Biological role of nitric oxide in platelet function. In: Moncada S, Higgs EA, Berrazueta ER, eds. Clinical Relevance of Nitric Oxide in the Cardiovascular System, Madrid, Spain: Edicomplet. 1991:45-56.
33. Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res. 1995;77:841-848.
34. Hjemdahl P, Larsson T, Wallén H. Effects of stress and β-blockade on platelet function. Circulation. 1991;84(suppl VI):VI-44-VI-61.
35. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325: 1551-1556.